Publication:
Effects of unplanned treatment interruptions on HIV treatment failure - results from TAHOD

dc.contributor.authorAwachana Jiamsakulen_US
dc.contributor.authorStephen J. Kerren_US
dc.contributor.authorOon Tek Ngen_US
dc.contributor.authorMan Po Leeen_US
dc.contributor.authorRomanee Chaiwarithen_US
dc.contributor.authorEvy Yunihastutien_US
dc.contributor.authorKinh Van Nguyenen_US
dc.contributor.authorT. T. Phamen_US
dc.contributor.authorSasisopin Kiertiburanakulen_US
dc.contributor.authorRossana Ditangcoen_US
dc.contributor.authorVonthanak Saphonnen_US
dc.contributor.authorBenedict L.H. Simen_US
dc.contributor.authorTuti Parwati Meratien_US
dc.contributor.authorWingwai Wongen_US
dc.contributor.authorPacharee Kantipongen_US
dc.contributor.authorFujie Zhangen_US
dc.contributor.authorJun Yong Choien_US
dc.contributor.authorSanjay Pujarien_US
dc.contributor.authorAdeeba Kamarulzamanen_US
dc.contributor.authorShinichi Okaen_US
dc.contributor.authorMahiran Mustafaen_US
dc.contributor.authorWinai Ratanasuwanen_US
dc.contributor.authorBoondarika Petersenen_US
dc.contributor.authorMatthew Lawen_US
dc.contributor.authorNagalingeswaran Kumarasamyen_US
dc.contributor.authorC. V. Meanen_US
dc.contributor.authorV. Kholen_US
dc.contributor.authorH. X. Zhaoen_US
dc.contributor.authorN. Hanen_US
dc.contributor.authorP. C.K. Lien_US
dc.contributor.authorW. Lamen_US
dc.contributor.authorY. T. Chanen_US
dc.contributor.authorS. Saghayamen_US
dc.contributor.authorC. Ezhilarasien_US
dc.contributor.authorK. Joshien_US
dc.contributor.authorS. Gaikwaden_US
dc.contributor.authorA. Chitalikaren_US
dc.contributor.authorD. N. Wirawanen_US
dc.contributor.authorF. Yulianaen_US
dc.contributor.authorD. Imranen_US
dc.contributor.authorA. Widhanien_US
dc.contributor.authorJ. Tanumaen_US
dc.contributor.authorT. Nishijimaen_US
dc.contributor.authorS. Naen_US
dc.contributor.authorJ. M. Kimen_US
dc.contributor.authorY. M. Ganien_US
dc.contributor.authorR. Daviden_US
dc.contributor.authorS. F. Syed Omaren_US
dc.contributor.authorS. Ponnampalavanaren_US
dc.contributor.authorI. Azwaen_US
dc.contributor.authorN. Nordinen_US
dc.contributor.authorE. Uyen_US
dc.contributor.authorR. Bantiqueen_US
dc.contributor.authorW. W. Kuen_US
dc.contributor.authorP. C. Wuen_US
dc.contributor.authorP. L. Limen_US
dc.contributor.authorL. S. Leeen_US
dc.contributor.authorP. S. Ohnmaren_US
dc.contributor.authorP. Phanuphaken_US
dc.contributor.authorK. Ruxrungthamen_US
dc.contributor.authorA. Avihingsanonen_US
dc.contributor.authorP. Chusuten_US
dc.contributor.authorS. Sungkanuparphen_US
dc.contributor.authorL. Chumlaen_US
dc.contributor.authorN. Sanmeemaen_US
dc.contributor.authorT. Sirisanthanaen_US
dc.contributor.authorW. Kotarathititumen_US
dc.contributor.authorJ. Praparattanapanen_US
dc.contributor.authorP. Kambuaen_US
dc.contributor.authorR. Sriondeeen_US
dc.contributor.authorV. H. Buien_US
dc.contributor.authorK. V. Nguyenen_US
dc.contributor.authorT. H.D. Nguyenen_US
dc.contributor.authorT. D. Nguyenen_US
dc.contributor.authorD. D. Cuongen_US
dc.contributor.authorH. L. Haen_US
dc.contributor.authorA. H. Sohnen_US
dc.contributor.authorN. Durieren_US
dc.contributor.authorD. A. Cooperen_US
dc.contributor.authorD. C. Boettigeren_US
dc.contributor.otherUniversity of New South Wales (UNSW) Australiaen_US
dc.contributor.otherThe HIV Netherlands Australia Thailand Research Collaborationen_US
dc.contributor.otherAcademic Medical Centre, University of Amsterdamen_US
dc.contributor.otherTan Tock Seng Hospitalen_US
dc.contributor.otherQueen Elizabeth Hospital Hong Kongen_US
dc.contributor.otherChiang Mai Universityen_US
dc.contributor.otherUniversity of Indonesia, RSUPN Dr. Cipto Mangunkusumoen_US
dc.contributor.otherNational Hospital for Tropical Diseasesen_US
dc.contributor.otherBach Mai Hospitalen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherGokilaen_US
dc.contributor.otherDermatology and STDs and University of Health Sciencesen_US
dc.contributor.otherHospital Sungai Bulohen_US
dc.contributor.otherUniversitas Udayanaen_US
dc.contributor.otherVeterans General Hospital-Taipeien_US
dc.contributor.otherChiangrai Prachanukroh Hospitalen_US
dc.contributor.otherBeijing Ditan Hospitalen_US
dc.contributor.otherYonsei University College of Medicineen_US
dc.contributor.otherInstitute of Infectious Diseasesen_US
dc.contributor.otherUniversity of Malaya Medical Centreen_US
dc.contributor.otherNational Center for Global Health and Medicineen_US
dc.contributor.otherHospital Raja Perempuan Zainab IIen_US
dc.contributor.otheramfAR - The Foundation for AIDS Researchen_US
dc.contributor.otherVHS Medical Centre Indiaen_US
dc.contributor.otherResearch Institute for Health Sciencesen_US
dc.date.accessioned2018-12-11T03:03:07Z
dc.date.accessioned2019-03-14T08:01:46Z
dc.date.available2018-12-11T03:03:07Z
dc.date.available2019-03-14T08:01:46Z
dc.date.issued2016-05-01en_US
dc.description.abstract© 2016 John Wiley & Sons Ltd. Objectives: Treatment interruptions (TIs) of combination antiretroviral therapy (cART) are known to lead to unfavourable treatment outcomes but do still occur in resource-limited settings. We investigated the effects of TI associated with adverse events (AEs) and non-AE-related reasons, including their durations, on treatment failure after cART resumption in HIV-infected individuals in Asia. Methods: Patients initiating cART between 2006 and 2013 were included. TI was defined as stopping cART for >1 day. Treatment failure was defined as confirmed virological, immunological or clinical failure. Time to treatment failure during cART was analysed using Cox regression, not including periods off treatment. Covariables with P < 0.10 in univariable analyses were included in multivariable analyses, where P < 0.05 was considered statistically significant. Results: Of 4549 patients from 13 countries in Asia, 3176 (69.8%) were male and the median age was 34 years. A total of 111 (2.4%) had TIs due to AEs and 135 (3.0%) had TIs for other reasons. Median interruption times were 22 days for AE and 148 days for non-AE TIs. In multivariable analyses, interruptions >30 days were associated with failure (31-180 days HR = 2.66, 95%CI (1.70-4.16); 181-365 days HR = 6.22, 95%CI (3.26-11.86); and >365 days HR = 9.10, 95% CI (4.27-19.38), all P < 0.001, compared to 0-14 days). Reasons for previous TI were not statistically significant (P = 0.158). Conclusions: Duration of interruptions of more than 30 days was the key factor associated with large increases in subsequent risk of treatment failure. If TI is unavoidable, its duration should be minimised to reduce the risk of failure after treatment resumption.en_US
dc.identifier.citationTropical Medicine and International Health. Vol.21, No.5 (2016), 662-674en_US
dc.identifier.doi10.1111/tmi.12690en_US
dc.identifier.issn13653156en_US
dc.identifier.issn13602276en_US
dc.identifier.other2-s2.0-84963722410en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/40852
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84963722410&origin=inwarden_US
dc.subjectImmunology and Microbiologyen_US
dc.titleEffects of unplanned treatment interruptions on HIV treatment failure - results from TAHODen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84963722410&origin=inwarden_US

Files

Collections